AU2018221322B2 - Amino pyrimidine compounds useful as SSAO inhibitors - Google Patents

Amino pyrimidine compounds useful as SSAO inhibitors Download PDF

Info

Publication number
AU2018221322B2
AU2018221322B2 AU2018221322A AU2018221322A AU2018221322B2 AU 2018221322 B2 AU2018221322 B2 AU 2018221322B2 AU 2018221322 A AU2018221322 A AU 2018221322A AU 2018221322 A AU2018221322 A AU 2018221322A AU 2018221322 B2 AU2018221322 B2 AU 2018221322B2
Authority
AU
Australia
Prior art keywords
mmol
tert
compound according
fluoro
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018221322A
Other languages
English (en)
Other versions
AU2018221322A1 (en
Inventor
Mengyang FAN
Luoheng QIN
Yi Wei
Guoqiang ZHOU
Jingye Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63169081&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018221322(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2018221322A1 publication Critical patent/AU2018221322A1/en
Application granted granted Critical
Publication of AU2018221322B2 publication Critical patent/AU2018221322B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2018221322A 2017-02-14 2018-02-07 Amino pyrimidine compounds useful as SSAO inhibitors Ceased AU2018221322B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/CN2017/000157 WO2018148856A1 (en) 2017-02-14 2017-02-14 Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors
AUPCT/CN2017/000157 2017-02-14
PCT/CN2017/117791 WO2018149226A1 (en) 2017-02-14 2017-12-21 Amino pyrimidine compounds useful as ssao inhibitors
AUPCT/CN2017/117791 2017-12-21
PCT/US2018/017152 WO2018151985A1 (en) 2017-02-14 2018-02-07 Amino pyrimidine compounds useful as ssao inhibitors

Publications (2)

Publication Number Publication Date
AU2018221322A1 AU2018221322A1 (en) 2019-08-15
AU2018221322B2 true AU2018221322B2 (en) 2022-04-14

Family

ID=63169081

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018221322A Ceased AU2018221322B2 (en) 2017-02-14 2018-02-07 Amino pyrimidine compounds useful as SSAO inhibitors

Country Status (13)

Country Link
US (2) US10278970B2 (enExample)
EP (1) EP3582780B1 (enExample)
JP (2) JP7030827B2 (enExample)
KR (1) KR20190117007A (enExample)
CN (2) CN114369095B (enExample)
AU (1) AU2018221322B2 (enExample)
CA (1) CA3052044A1 (enExample)
DK (1) DK3582780T3 (enExample)
ES (1) ES2897666T3 (enExample)
IL (1) IL268625A (enExample)
MX (1) MX2019009501A (enExample)
SG (2) SG11201907032RA (enExample)
WO (3) WO2018148856A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
WO2018148856A1 (en) 2017-02-14 2018-08-23 Eli Lilly And Company Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors
CN109251166B (zh) * 2017-07-13 2021-11-05 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
CN109810041B (zh) * 2017-11-21 2023-08-15 药捷安康(南京)科技股份有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
CN109988106B (zh) * 2017-12-29 2023-03-31 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
US20210238192A1 (en) * 2018-06-29 2021-08-05 Blade Therapeutics, Inc. Vascular adhesion protein-1 (vap-1) modulators and therapeutic uses thereof
CN110938059A (zh) * 2018-09-25 2020-03-31 上海轶诺药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用
WO2020063854A1 (zh) * 2018-09-27 2020-04-02 南京明德新药研发有限公司 作为vap-1抑制剂的喹啉类衍生物
JP7425793B2 (ja) 2018-10-29 2024-01-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジニルスルホンアミド誘導体、医薬組成物およびそれらの使用
CA3112510A1 (en) 2018-10-29 2020-05-07 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
AU2020206477B2 (en) * 2019-01-11 2022-11-10 Transthera Sciences (Nanjing), Inc. Haloallylamine compounds and application thereof
CN111471037B (zh) * 2019-01-23 2023-02-10 药捷安康(南京)科技股份有限公司 烯丙基胺类化合物及其应用
MX2022005199A (es) 2019-10-29 2022-08-04 Eccogene Shanghai Co Ltd Inhibidores de ssao y uso de los mismos.
CN113149957A (zh) 2020-01-23 2021-07-23 轶诺(浙江)药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用
PE20231096A1 (es) 2020-08-25 2023-07-18 Lilly Co Eli Polimorfos de un inhibidor de ssao

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140315882A1 (en) * 2013-04-17 2014-10-23 Boehringer Ingelheim International Gmbh Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008123469A1 (ja) 2007-03-30 2008-10-16 Japan Tobacco Inc. 6員環アミド化合物およびその用途
WO2009012573A1 (en) 2007-07-20 2009-01-29 Merck Frosst Canada Ltd. Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US8426587B2 (en) 2007-11-21 2013-04-23 Pharmaxis Ltd. Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor
EP2479165B1 (en) * 2009-09-16 2017-10-25 Astellas Pharma Inc. Glycine compound
JP2011136942A (ja) 2009-12-28 2011-07-14 Kowa Co 新規な置換ピリミジン誘導体およびこれを含有する医薬
KR101879011B1 (ko) * 2011-03-15 2018-07-16 아스테라스 세이야쿠 가부시키가이샤 구아니딘 화합물
CA2871793C (en) 2012-05-02 2020-09-15 Pharmaxis Ltd. Substituted 3-haloallylamine inhibitors of ssao and uses thereof
EA201590953A1 (ru) 2012-11-16 2015-08-31 Бристол-Майерс Сквибб Компани Пирролидиновые модуляторы gpr40
WO2014184104A1 (en) 2013-05-17 2014-11-20 Boehringer Ingelheim International Gmbh Pyrrolidine derivatives, pharmaceutical compositions and uses thereof
GB201416444D0 (en) * 2014-09-17 2014-10-29 Proximagen Ltd New compounds
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
WO2018148856A1 (en) 2017-02-14 2018-08-23 Eli Lilly And Company Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140315882A1 (en) * 2013-04-17 2014-10-23 Boehringer Ingelheim International Gmbh Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof

Also Published As

Publication number Publication date
WO2018148856A1 (en) 2018-08-23
US20180296560A1 (en) 2018-10-18
US10471060B2 (en) 2019-11-12
CN114369095A (zh) 2022-04-19
EP3582780B1 (en) 2021-10-13
US20190275041A1 (en) 2019-09-12
JP2022068325A (ja) 2022-05-09
WO2018151985A1 (en) 2018-08-23
CN108778278A (zh) 2018-11-09
ES2897666T3 (es) 2022-03-02
AU2018221322A1 (en) 2019-08-15
IL268625A (en) 2019-10-31
CN114369095B (zh) 2025-03-14
CA3052044A1 (en) 2018-08-23
JP7030827B2 (ja) 2022-03-07
KR20190117007A (ko) 2019-10-15
DK3582780T3 (da) 2021-11-01
SG11201907032RA (en) 2019-08-27
JP7247389B2 (ja) 2023-03-28
WO2018149226A1 (en) 2018-08-23
CN108778278B (zh) 2022-01-28
EP3582780A1 (en) 2019-12-25
JP2020507589A (ja) 2020-03-12
US10278970B2 (en) 2019-05-07
MX2019009501A (es) 2019-11-05
SG10201913492YA (en) 2020-03-30

Similar Documents

Publication Publication Date Title
JP7247389B2 (ja) Ssao阻害剤として有用なアミノピリミジン化合物
ES2963417T3 (es) Derivados de imidazol condensados como moduladores de IL-17
ES2865199T3 (es) Compuestos de heteroarilo o arilo condensados bicíclicos como moduladores de IRAK4
US12559506B2 (en) Indazole based compounds and associated methods of use
CA2877550C (en) Imidazopyridine derivatives as modulators of tnf activity
US8003649B2 (en) Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155
IL297833A (en) Heterocyclic compounds as a stimulating receptor expressed in myeloid cells 2 agonists and methods of use
JP2013521290A (ja) Mglur2の正のアロステリックモジュレータ
MX2014011373A (es) Inhibidores de diacilglicerol aciltransferasa 2.
EA024123B1 (ru) Тетрагидропиридопиримидиновые производные
US10851116B2 (en) Bicyclic amines as novel JAK kinase inhibitors
TW202039459A (zh) Alk5 抑制劑
US20250332266A1 (en) Compounds for the degradation of egfr kinase
EP3481823B1 (de) 7-substituierte 1-pyridyl-naphthyridin-3-carbonsäureamide und ihre verwendung
US20240101540A1 (en) Targeted protein degradation of parp14 for use in therapy
US20240425523A1 (en) Compounds for the Degradation of EGFR Kinase
US20220306619A1 (en) Pro drugs of pde10 compounds
HK40000285A (en) Amino pyrimidine compounds useful as ssao inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)